Literature DB >> 16940762

Potential role of N-methyl-D-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine.

Gary L Wenk1, Chris G Parsons, Wojciech Danysz.   

Abstract

Glutamatergic neurotransmission is critical to normal learning and memory and when the activity of glutamate neurons becomes excessive, or the normal function of its primary receptors becomes dysfunctional, this may lead to pathological changes associated with age-related neurodegenerative diseases. Anomalous glutamatergic activity associated with Alzheimer's disease may be due to a postsynaptic receptor and downstream defects that produce inappropriately timed or sustained glutamate activation of N-methyl-D-aspartate receptors, leading to neuronal injury and death and cognitive deficits associated with dementia. The mechanisms leading to the condition of chronically depolarized membranes on vulnerable neurons in the Alzheimer's disease brain are likely due to a complex interaction between oxidative stress, mitochondrial failure, chronic brain inflammation and the presence of amyloid-beta and hyperphosphorylated-tau; each of these factors are highly interrelated with each other and are discussed with an emphasis upon potential therapeutic mechanisms underlying the neuroprotective actions of memantine.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16940762     DOI: 10.1097/00008877-200609000-00007

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  34 in total

Review 1.  Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections.

Authors:  Wojciech Danysz; Chris G Parsons
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

2.  Memantine decreases hippocampal glutamate levels: a magnetic resonance spectroscopy study.

Authors:  Lidia Glodzik; Kevin G King; Oded Gonen; Songtao Liu; Susan De Santi; Mony J de Leon
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2008-02-07       Impact factor: 5.067

Review 3.  Inflammation and aging: can endocannabinoids help?

Authors:  Yannick Marchalant; Holly M Brothers; Gary L Wenk
Journal:  Biomed Pharmacother       Date:  2008-03-14       Impact factor: 6.529

4.  Anti-inflammatory property of the cannabinoid agonist WIN-55212-2 in a rodent model of chronic brain inflammation.

Authors:  Y Marchalant; S Rosi; G L Wenk
Journal:  Neuroscience       Date:  2006-12-18       Impact factor: 3.590

Review 5.  Therapeutic strategies for Alzheimer's disease.

Authors:  Donna M Barten; Charles F Albright
Journal:  Mol Neurobiol       Date:  2008-06-26       Impact factor: 5.590

6.  Effects of memantine on cerebrospinal fluid biomarkers of neurofibrillary pathology.

Authors:  Lidia Glodzik; Susan De Santi; Kenneth E Rich; Miroslaw Brys; Elizabeth Pirraglia; Rachel Mistur; Remigiusz Switalski; Lisa Mosconi; Martin Sadowski; Henrik Zetterberg; Kaj Blennow; Mony J de Leon
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

7.  Cannabinoid receptor stimulation is anti-inflammatory and improves memory in old rats.

Authors:  Yannick Marchalant; Francesca Cerbai; Holly M Brothers; Gary L Wenk
Journal:  Neurobiol Aging       Date:  2007-06-11       Impact factor: 4.673

8.  Effects of exogenous heat shock protein 70 and quercetin on NMDA-induced seizures.

Authors:  I V Ekimova; T G Komarova; L E Nitsinskaya; Yu F Pastukhov; I V Guzhova
Journal:  Dokl Biol Sci       Date:  2011-01-18

9.  Pharmacodynamics of memantine: an update.

Authors:  G Rammes; W Danysz; C G Parsons
Journal:  Curr Neuropharmacol       Date:  2008-03       Impact factor: 7.363

10.  Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults.

Authors:  Robert H Howland
Journal:  Neuropsychiatr Dis Treat       Date:  2009-11-16       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.